Sector Expert: John McCamant

Medical Technology Stock Letter

Image: John McCamant

John McCamant is the editor of the Medical Technology Stock Letter, a leading investment newsletter. McCamant has spent 25 years on the frontlines of biotechnology investing. He has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Reuters, Bloomberg, CBS and Marketwatch.

Subscribe to
Streetwise Reports

Companies Commented On

  • Esperion Therapeutics
  • Madrigal Pharmaceuticals Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Sangamo BioSciences Inc.


Recent Interviews

Biotech Round-Up: M&As, Financings and Immuno-Oncology (4/18/18)
Beaker

John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline.

Biotech Delivers 'Excellent' Phase 2 Data (4/3/18)
Blood test

John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial.

Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018 (1/10/18)
Pills

As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline.

Recent Quotes

"CBMG is putting together a huge portfolio of assets in cancer."

The Life Sciences Report Interview with John McCamant (9/16/15)
more >

"CBMG's world-class pipeline is still below Wall Street's radar."

— John McCamant, Medical Technology Stock Letter (6/11/15)
more >

"CBMG is a recently transformed company."

The Life Sciences Report with John McCamant (5/12/15)
more >

"We continue to believe that OGXI is undervalued."

— John McCamant, Medical Technology Stock Letter (12/21/12)
more >

"The potential of CYCC's phase 3 trial with AML gives the Street more confidence."

The Life Sciences Report Interview with John McCamant (10/25/12)
more >

"If OGXI-011 starts delivering in phase 3, OGXI could be a five- or tenbagger."

The Life Sciences Report Interview with John McCamant (10/4/12)
more >

"We continue to believe that OGXI is undervalued."

— John McCamant, Medical Technology Stock Letter (7/20/12)
more >

"Data from OGXI's phase 2 trial for OGX-427 is encouraging."

— John McCamant, Medical Technology Stock Letter (6/8/12)
more >



Due to permission requirements, not all quotes are shown.